Cargando…

Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma

The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsutsumi, Yutaka, Nakayama, Chie, Kamada, Koki, Kikuchi, Ryo, Kudo, Daiki, Ito, Shinichi, Matsuoka, Satomi, Shiratori, Souichi, Yamamoto, Yoshiya, Naruse, Hirohito, Teshima, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691112/
https://www.ncbi.nlm.nih.gov/pubmed/28939993
http://dx.doi.org/10.1007/s00277-017-3129-0
_version_ 1783279730667028480
author Tsutsumi, Yutaka
Nakayama, Chie
Kamada, Koki
Kikuchi, Ryo
Kudo, Daiki
Ito, Shinichi
Matsuoka, Satomi
Shiratori, Souichi
Yamamoto, Yoshiya
Naruse, Hirohito
Teshima, Takanori
author_facet Tsutsumi, Yutaka
Nakayama, Chie
Kamada, Koki
Kikuchi, Ryo
Kudo, Daiki
Ito, Shinichi
Matsuoka, Satomi
Shiratori, Souichi
Yamamoto, Yoshiya
Naruse, Hirohito
Teshima, Takanori
author_sort Tsutsumi, Yutaka
collection PubMed
description The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2). All the cases were in remission at the time of initial treatment. There were no significant differences between the three groups in terms of age, sex, treatment, stage, or International Prognosis Index (IPI). When HCV antiviral therapy was performed after treatment for diffuse large-cell lymphoma, we observed no recurrence or deaths, and the 2-year overall survival and progression-free survival rates were significantly greater than those in the control 1 group (P = 0.0246). It is possible that a better prognosis can be achieved by performing HCV antiviral therapy after achieving remission in cases of HCV-RNA-positive diffuse large-cell lymphoma through the use of R-CHOP or similar treatments.
format Online
Article
Text
id pubmed-5691112
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56911122017-11-30 Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma Tsutsumi, Yutaka Nakayama, Chie Kamada, Koki Kikuchi, Ryo Kudo, Daiki Ito, Shinichi Matsuoka, Satomi Shiratori, Souichi Yamamoto, Yoshiya Naruse, Hirohito Teshima, Takanori Ann Hematol Original Article The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2). All the cases were in remission at the time of initial treatment. There were no significant differences between the three groups in terms of age, sex, treatment, stage, or International Prognosis Index (IPI). When HCV antiviral therapy was performed after treatment for diffuse large-cell lymphoma, we observed no recurrence or deaths, and the 2-year overall survival and progression-free survival rates were significantly greater than those in the control 1 group (P = 0.0246). It is possible that a better prognosis can be achieved by performing HCV antiviral therapy after achieving remission in cases of HCV-RNA-positive diffuse large-cell lymphoma through the use of R-CHOP or similar treatments. Springer Berlin Heidelberg 2017-09-22 2017 /pmc/articles/PMC5691112/ /pubmed/28939993 http://dx.doi.org/10.1007/s00277-017-3129-0 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Tsutsumi, Yutaka
Nakayama, Chie
Kamada, Koki
Kikuchi, Ryo
Kudo, Daiki
Ito, Shinichi
Matsuoka, Satomi
Shiratori, Souichi
Yamamoto, Yoshiya
Naruse, Hirohito
Teshima, Takanori
Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title_full Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title_fullStr Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title_full_unstemmed Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title_short Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
title_sort efficacy and prognosis of antiviral therapy on hepatitis c following treatment of lymphoma in hcv-positive diffuse large-cell lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691112/
https://www.ncbi.nlm.nih.gov/pubmed/28939993
http://dx.doi.org/10.1007/s00277-017-3129-0
work_keys_str_mv AT tsutsumiyutaka efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT nakayamachie efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT kamadakoki efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT kikuchiryo efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT kudodaiki efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT itoshinichi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT matsuokasatomi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT shiratorisouichi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT yamamotoyoshiya efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT narusehirohito efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma
AT teshimatakanori efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma